bpc-157 latest studies BPC-157: Tendon Repair and More BPC-157 for athletes and injury
Description
In one DAXI study, 95.7% of participants were somewhat satisfied, satisfied, or very satisfied with their results after four weeks, with the highest number of participants describing themselves as very satisfied
It does not have extensive human clinical trial data demonstrating safety and efficacy for specific medical conditions
Phillip S Verified Customer Highly Recommend
doi: 10.47855/jal9020-2021-1-3
A phase I trial involving 40 patients with relapsed/refractory HL that the combination of Vorinostat (300 mg/day orally) with sirolimus (4 mg/day orally, n=22) or Everolimus (5-10 mg/day dose escalation, n=18) yielded ORR of 55% and 33%, respectively, with a median progression-free survival (PFS) of 5.8 months, suggesting synergistic efficacy of HDACi combined with mTOR inhibitors (90)
Cervical myelopathy: a clinical and radiographic evaluation and correlation to cervical spondylotic myelopathy
